Tango Therapeutics Inc (TNGX NASDAQ) stock market data APIs
$17.1541
0.05(0.3%)
as of March 13, 2026
Try our APIs with
free plan!
Tango Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Prev. Close
17.1541
Open
17.3122
High
17.4083
Low
16.7267
52 wk Range
1.03-17.63
Market Cap
2 469 M
Shares Outstanding
143 M
Revenue
62 384 K
EPS
-0.14
Beta
1.815
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tango Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tango Therapeutics Inc data using free add-ons & libraries
Get Tango Therapeutics Inc Fundamental Data
Tango Therapeutics Inc Fundamental data includes:
- Net Revenue: 62 384 K
- EBITDA: -109 008 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tango Therapeutics Inc News
New
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. ...
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Quick Read X4 Pharmaceuticals (XFOR) at $3.97, target $12, raised $240.3M; Immuneering (IMRX) at $5.48, target $12; Tango Therapeutics (TNGX) at $16.60, target $24, up 87.25% YTD, 43.89% past week. X...
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
Boxer Capital Management, LLC reported a buy of 386,000 Kodiak Sciences(NASDAQ:KOD) shares in its February 17, 2026, SEC filing, an estimated $7.90 million trade based on quarterly average pricing. W...
Tango Therapeutics (TNGX) Soars 52% on Buy Reco
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 Stocks Investors Are Watching Closely This Week. Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry ...
Get Tango Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
